Comment from Biotechnology Innovation Organization

Summary: The Biotechnology Innovation Organization (BIO) supports the FDA's draft guidance on New Approach Methodologies (NAMs) as a step toward modernizing nonclinical safety assessments and reducing animal testing. They request additional clarity on regulatory decision-making, validation requirements, and specific implementation details to provide sponsors with greater confidence and consistency.